Rucaparib latest price reference in 2025

Rucaparib has been an important member of the PARP inhibitor family since it was approved by the US FDA in December 2016. Its clinical application value is mainly reflected in the treatment of ovarian cancer and other gynecological tumors, especially in patients with recurrent diseases and patients carrying BRCA gene mutations. Overseas guidelines usually recommend it as maintenance therapy or as a re-treatment option after disease progression, thereby delaying patient disease progression and improving overall survival prognosis. In actual use, rucapanib relies on the convenience of oral preparations, allowing patients to reduce frequent intravenous infusions and significantly improve their quality of life compared with previous treatment methods.

In terms of price, rucapanib is not currently available in mainland China and therefore cannot be included in the medical insurance reimbursement system. According to overseas channels, the sales specification of rucapanib in the United States is 300mg*60 tablets, with a price of approximately RMB 38,000. It should be noted that this price is mainly based on the pricing of the original drug, and there is currently no relevant version of the generic drug, which to a certain extent results in higher drug costs. For Chinese patients, if they need to use the drug, they usually need to obtain it through cross-border drug purchase channels, which also limits its accessibility.

From the perspective of the global market structure, rucapanib has formed similar competition with PARP inhibitors such as olaparib (Olaparib) and niraparib (Niraparib). Different drugs have different indication expansion, tolerance and long-term efficacy, but rucapanib still has advantages in the treatment of some recurrent ovarian cancer due to its specific molecular properties. With the continuous updating of overseas research, rucapanib is also trying to expand to a wider range of indications such as prostate cancer and pancreatic cancer, and the market space is expected to further expand in the future.

Reference materials:https://www.drugs.com/mtm/rucaparib.html